Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria
- PMID: 31298061
- DOI: 10.1080/23744235.2019.1640386
Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria
Abstract
Background: Polymyxin B and colistin have similar structures except for one amino acid. Usually, physicians choose either polymyxin B or colistin for treatment of infections caused by multidrug-resistant (MDR) organisms. The preference is based on previous experience. Not much data are found in the literature comparing the two drugs against the same microorganisms. In this study, we compared in vitro antimicrobial activities of the two polymyxins against a panel of highly resistant and susceptible microorganisms. Methods: Eighty-nine clinical isolates (27 Klebsiella pneumoniae, 31 Acinetobacter baumannii and 31 Pseudomonas aeruginosa) were tested in broth microdilution assays. Time-kill curve experiments were carried out on selected isolates. Results: Significantly lower MICs for polymyxin B than for colistin were found against all species tested including K. pneumoniae (p < .02), A. baumannii (p < .001) and P. aeruginosa (p < .01). The low MICs caused a change in categorical interpretations of only two K. pneumoniae and two P. aeruginosa. Similar results were obtained in time-kill curve experiments with both susceptible and resistant clinical isolates. Conclusions: Significantly lower MICs were found for polymyxin B against three of the most critical MDR species. Even though differences in categorical interpretations were not striking, lower MICs might be a critical consideration in clinical management of select cases where the concentration of these toxic antibiotics matters because of underlying co-morbidities. These results provide support to previous suggestions that re-consideration of breakpoint interpretations for polymyxins might be needed.
Keywords: activity; Gram-negative; Polymyxin B; colistin; multi drug resistant.
Similar articles
-
A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01677-19. doi: 10.1128/AAC.01677-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844003 Free PMC article.
-
[Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].Mikrobiyol Bul. 2010 Apr;44(2):203-10. Mikrobiyol Bul. 2010. PMID: 20549954 Turkish.
-
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.Microb Drug Resist. 2017 Jul;23(5):640-650. doi: 10.1089/mdr.2016.0196. Epub 2016 Dec 9. Microb Drug Resist. 2017. PMID: 27935770
-
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.Int J Antimicrob Agents. 2005 Jan;25(1):11-25. doi: 10.1016/j.ijantimicag.2004.10.001. Int J Antimicrob Agents. 2005. PMID: 15620821 Review.
-
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8. Expert Rev Anti Infect Ther. 2023. PMID: 36820511 Review.
Cited by
-
Prevention of donation-related infections: investigating the use of antibiotics in the decontamination of preservation fluid for organ transplantation.Front Cell Infect Microbiol. 2025 Jul 23;15:1572799. doi: 10.3389/fcimb.2025.1572799. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40771313 Free PMC article.
-
Polymyxins: recent advances and challenges.Front Pharmacol. 2024 Jun 21;15:1424765. doi: 10.3389/fphar.2024.1424765. eCollection 2024. Front Pharmacol. 2024. PMID: 38974043 Free PMC article. Review.
-
Synergistic effects of polymyxin and vancomycin combinations on carbapenem- and polymyxin-resistant Klebsiella pneumoniae and their molecular characteristics.Microbiol Spectr. 2023 Dec 12;11(6):e0119923. doi: 10.1128/spectrum.01199-23. Epub 2023 Oct 31. Microbiol Spectr. 2023. PMID: 37905823 Free PMC article.
-
[Significance of Lipopolysaccharide Lipid A Gene Mutation of Extensively Drug-resistant Acinetobacter baumanii on Polymyxin Resistance and Its Influence on Treatment].Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Jan;52(1):124-128. doi: 10.12182/20210160208. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021. PMID: 33474901 Free PMC article. Chinese.
-
Effects of Aerosol Inhalation Combined with Intravenous Drip of Polymyxin B on Bacterial Clearance, Symptoms Improvement, and Serum Infection Indexes in Patients with Pneumonia Induced by Multidrug-Resistant Gram-Negative Bacteria.Emerg Med Int. 2022 Aug 28;2022:5244538. doi: 10.1155/2022/5244538. eCollection 2022. Emerg Med Int. 2022. PMID: 36072613 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical